Both Spero Therapeutics Inc. (NASDAQ:SPRO) and CRISPR Therapeutics AG (NASDAQ:CRSP) are Biotechnology companies, competing one another. We will compare their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Spero Therapeutics Inc. 11 -0.15 12.36M -2.18 0.00
CRISPR Therapeutics AG 56 0.00 34.37M -3.74 0.00

In table 1 we can see Spero Therapeutics Inc. and CRISPR Therapeutics AG’s gross revenue, earnings per share and valuation.


Table 2 shows the return on equity, return on assets and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Spero Therapeutics Inc. 114,127,423.82% -34.5% -31.2%
CRISPR Therapeutics AG 61,805,430.68% -50.9% -39.8%


Spero Therapeutics Inc.’s Current Ratio is 17.5 while its Quick Ratio is 17.5. On the competitive side is, CRISPR Therapeutics AG which has a 15.8 Current Ratio and a 15.8 Quick Ratio. Spero Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to CRISPR Therapeutics AG.

Analyst Ratings

In next table is delivered Spero Therapeutics Inc. and CRISPR Therapeutics AG’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Spero Therapeutics Inc. 0 0 1 3.00
CRISPR Therapeutics AG 0 0 4 3.00

Spero Therapeutics Inc. has a 193.13% upside potential and a consensus price target of $35. Competitively CRISPR Therapeutics AG has a consensus price target of $66.5, with potential downside of -8.11%. Based on the data delivered earlier, Spero Therapeutics Inc. is looking more favorable than CRISPR Therapeutics AG, analysts belief.

Institutional & Insider Ownership

Institutional investors owned 53.1% of Spero Therapeutics Inc. shares and 50% of CRISPR Therapeutics AG shares. Insiders owned roughly 23.71% of Spero Therapeutics Inc.’s shares. Insiders Comparatively, owned 2% of CRISPR Therapeutics AG shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Spero Therapeutics Inc. -0.95% -11.87% -4.77% 9.14% -5.63% 68.94%
CRISPR Therapeutics AG 3.15% 6.25% 30.58% 57.23% 7.51% 77.42%

For the past year Spero Therapeutics Inc. has weaker performance than CRISPR Therapeutics AG


Spero Therapeutics Inc. beats on 7 of the 11 factors CRISPR Therapeutics AG.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Source link